17,261 trials
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Severe Alzheimer Disease
Primary: Frequency of Treatment-emergent Adverse Events (Safety) — 8; 3 Participants
Shigellosis
Primary: Attack Rate of Shigellosis in Vaccinated Subjects. — 13; 18 Participants
Parenteral Nutrition Associated Cholestasis
Primary: Normalization of Conjugated Bilirubin (Conjugated Bilirubin < 2 mg/dL) — 2 mg/dl
Late Complication From Kidney Transplant
Primary: Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months — 3; 10 Participants — p=0.033
Curvature of Spine
Primary: Total Red Blood Cells Transfused in the Intraoperative Period — 1140; 1460 milliliters — p=.05
Brain Neoplasms, Adult, Malignant
Primary: Mean Change in *Delayed* Recall Score by Hopkins Verbal Learning Test-Revised (HVLT-R DR) Score — -10.6 percentage difference
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Treatment Related Mortality — 0; 0; 0; 0 participants
Cardiac Failure · Myocardial Failure · Congestive Heart Failure
Primary: 4-hour Urinary Output Following Intravenous Administration of 40 mg Furosemide to HFrEF Participants Receiving BMS-986231 Infusion Compared to Placebo — 900.7; 1603.3…
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Cancer
Primary: Cancer Detection Performance of FACBC PET/CT — 17; 22; 4; 14 Participants
Prostate Cancer
Primary: Percentage of Participants With an Immune Response to Prostatic Acid Phosphatase (PAP) and/or PA2024 — 71.4; 87.5 percentage of participants
Multiple Myeloma
Primary: Serious Adverse Events — 23; 23; 4; 1 Events
Esophagogastric Adenocarcinoma
Primary: 6-month Progression-free Survival (PFS) — 1.9 months